LLY Stock Rallies On Much Awaited FDA Approval For Weight Loss Pill

• The company said that the drug, sold ​under the brand name Foundayo, will be available first via Lilly’s online pharmacy called LillyDirect, with shipping starting April 6.
• In a late-stage trial, individuals taking the highest dose of orforglipron and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo.
• Lilly’s rival Novo Nordisk launched its weight loss pill to commendable reception in January, giving the Danish drugmaker a solid head start against its American competitor.

Shares of Eli Lilly and Company (LLY) rallied 4% on Wednesday after the U.S. Food and Drug Administration approved its oral weight loss drug orforglipron, helping build its rivalry with Danish drugmaker Novo Nordisk (NVO) for dominance in the obesity segment.

The drug is now approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

Availability And Trial Outcomes

The company said that the drug, sold ​under the brand name Foundayo, will be available first via Lilly’s online pharmacy called LillyDirect, with shipping starting April 6. The pill will later be made available through U.S. retail pharmacies and telehealth providers.

In a late-stage trial, individuals taking the highest dose of orforglipron and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo. The drug also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.

Pricing

Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose, Lilly said. Further, eligible Medicare Part D individuals may be able to get the pill for $50 per month, beginning as soon as July 1, 2026, it added.

Oral obesity pills are expected to be the next major innovation in the obesity market, doing away with needles and offering customers more flexibility and ease. The FDA approved Lilly’s rival Novo Nordisk’s oral obesity pill called Wegovy in December. Novo launched it to commendable reception in January, giving the Danish drugmaker a solid head start against its American competitor.

How Did Retail Traders React?

On Stocktwits, retail sentiment around LLY stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.

LLY stock has gained 19% over the past 12 months.

Read More: SpaceX Files Confidentially For IPO, Setting Stage For Record-Breaking Market Debut: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.